Latest Period
Q4 2025
Security Snapshot
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) Institutional Ownership
CUSIP: 98422T100
13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026
Institutions Reporting
37
Shares (Excl. Options)
39,727,815
Price
$0.64
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- XLO on Nasdaq
- Shares outstanding
- 73,644,024
- Price per share
- $8.41
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 39,727,815
- Total reported value
- $25,433,377
- % of total 13F portfolios
- 0%
- Share change
- +17,967,980
- Value change
- +$11,324,174
- Number of holders
- 37
- Price from insider filings
- $8.41
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 98422T100.
- 37 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 37 to 1 between Q4 2025 and Q1 2026.
- Reported value moved from $25,433,377 to $5,469,771.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 37 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 98422T100?
CUSIP 98422T100 identifies XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 98422T100:
Significant Owners of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 20% | 0% | $9,581,667 | +$2,576,464 | 14,517,678 | +37% | GILEAD SCIENCES, INC. | 31 Dec 2025 |
| Point72 Asset Management, L.P. | 9.9% | +39% | $6,743,200 | +$3,371,600 | 8,000,000 | +100% | Point72 Asset Management, L.P. | 30 Sep 2025 |
| Bain Capital Life Sciences Fund II, L.P. | 8.5% | $4,131,430 | 6,259,742 | BCLS II Equity Opportunities, LP | 31 Dec 2025 | |||
| STEMPOINT CAPITAL LP | 8.4% | +17% | $3,979,818 | +$1,339,818 | 6,030,028 | +51% | StemPoint Capital LP | 31 Dec 2025 |
| Coastlands Capital LP | 10% | $3,742,248 | 5,346,069 | Coastlands Capital LP | 04 Dec 2025 | |||
| Frazier Life Sciences Public Fund, L.P. | 6.7% | -32% | $3,086,472 | -$2,286,600 | 4,676,472 | -43% | Frazier Life Sciences Public Fund, L.P. | 31 Dec 2025 |
| AbbVie Inc. | 9% | $3,304,348 | 4,347,826 | AbbVie Inc. | 11 Feb 2025 |
As of 31 Dec 2025, 37 institutional investors reported holding 39,727,815 shares of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO). This represents 54% of the company’s total 73,644,024 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) together control 54% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 12% | 9,105,451 | 0% | 0.3% | $5,829,310 |
| Bain Capital Life Sciences Investors, LLC | 10% | 7,372,686 | +61% | 0.36% | $4,719,994 |
| Frazier Life Sciences Management, L.P. | 8% | 5,915,091 | 0.1% | $3,786,841 | |
| Point72 Asset Management, L.P. | 5.4% | 4,000,000 | 0% | $2,560,800 | |
| Sio Capital Management, LLC | 2.9% | 2,134,537 | 0.23% | $1,366,531 | |
| STEMPOINT CAPITAL LP | 2.8% | 2,030,028 | 0.22% | $1,299,624 | |
| Merck & Co., Inc. | 2% | 1,483,758 | 0% | 0.34% | $949,902 |
| VANGUARD GROUP INC | 1.7% | 1,255,692 | 0% | 0% | $803,643 |
| Empery Asset Management, LP | 1.6% | 1,183,040 | 0% | 0.67% | $757,382 |
| Ghisallo Capital Management LLC | 1.5% | 1,113,222 | 0.03% | $712,685 | |
| MORGAN STANLEY | 1.1% | 839,850 | -13% | 0% | $537,672 |
| AJU IB Investment Co., Ltd. | 0.91% | 667,742 | 0% | 2.3% | $427,488 |
| FMR LLC | 0.69% | 511,820 | 0% | 0% | $327,667 |
| CITADEL ADVISORS LLC | 0.59% | 436,216 | 0% | $279,265 | |
| RENAISSANCE TECHNOLOGIES LLC | 0.47% | 344,416 | +68% | 0% | $220,495 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.45% | 328,972 | 0% | 0% | $210,630 |
| STATE STREET CORP | 0.25% | 186,390 | +14% | 0% | $119,327 |
| Velan Capital Investment Management LP | 0.23% | 170,000 | 0.06% | $108,834 | |
| GSA CAPITAL PARTNERS LLP | 0.2% | 147,966 | 0.01% | $95,000 | |
| Stonepine Capital Management, LLC | 0.17% | 126,270 | 0.06% | $80,838 | |
| NORTHERN TRUST CORP | 0.09% | 66,609 | 0% | 0% | $42,643 |
| TWO SIGMA INVESTMENTS, LP | 0.08% | 62,032 | -29% | 0% | $39,713 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.08% | 56,081 | 0% | 0% | $35,903 |
| JANE STREET GROUP, LLC | 0.06% | 42,080 | 0% | $26,940 | |
| HRT FINANCIAL LP | 0.04% | 31,886 | +29% | 0% | $20,000 |
Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 650,389 | $5,469,771 | -$72,414,218 | $8.41 | 1 |
| 2025 Q4 | 39,727,815 | $25,433,377 | +$11,324,174 | $0.64 | 37 |
| 2025 Q3 | 22,051,916 | $18,613,906 | -$1,227,318 | $0.84 | 36 |
| 2025 Q2 | 23,795,263 | $16,179,092 | +$854,217 | $0.68 | 35 |
| 2025 Q1 | 22,528,206 | $16,318,555 | -$3,181,066 | $0.72 | 35 |
| 2024 Q4 | 25,814,355 | $24,660,128 | -$144,644 | $0.96 | 34 |
| 2024 Q3 | 15,911,945 | $12,534,583 | +$1,128,156 | $0.79 | 32 |
| 2024 Q2 | 14,508,823 | $13,746,216 | +$1,785,264 | $0.95 | 31 |
| 2024 Q1 | 12,460,895 | $13,460,257 | -$2,676,053 | $1.08 | 30 |
| 2023 Q4 | 16,426,281 | $9,034,716 | -$1,543,598 | $0.55 | 33 |
| 2023 Q3 | 15,860,160 | $33,465,952 | -$314,935 | $2.11 | 30 |
| 2023 Q2 | 16,002,286 | $41,925,598 | -$192,245 | $2.62 | 32 |
| 2023 Q1 | 16,072,057 | $50,979,505 | +$461,644 | $3.17 | 32 |
| 2022 Q4 | 15,926,513 | $42,841,966 | -$709,927 | $2.69 | 28 |
| 2022 Q3 | 16,606,568 | $48,328,000 | -$3,750,524 | $2.91 | 28 |
| 2022 Q2 | 17,880,380 | $52,211,910 | -$3,647,986 | $2.92 | 29 |
| 2022 Q1 | 18,775,939 | $132,746,000 | -$2,569,332 | $7.07 | 41 |
| 2021 Q4 | 18,324,586 | $269,421,063 | +$225,248,000 | $16.00 | 41 |